Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 310 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Anthracyclines in Early Breast Cancer: The Long Goodbye.
Grinda T, Burstein HJ
J Clin Oncol, JCO2401916, 05 Nov 2024
Cited by: 0 articles | PMID: 39499830
Add to export list
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.
Wong JS, Uno H, Tramontano AC, Fisher L, Pellegrini CV, Abel GA, Burstein HJ, Chun YS, King TA, Schrag D, Winer E, Bellon JR, Cheney MD, Hardenbergh P, Ho A, Horst KC, Kim JN, Leonard KL, Moran MS, [...] Punglia RS
JAMA Oncol, 10(10):1370-1378, 01 Oct 2024
Cited by: 0 articles | PMID: 39115975
Add to export list
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.
Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A
JCO Oncol Pract, OP2400547, 27 Aug 2024
Cited by: 0 articles | PMID: 39190846
Add to export list
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, [...] TBCRC Translational Investigators
J Clin Oncol, 42(31):3652-3665, 27 Jun 2024
Cited by: 4 articles | PMID: 38935923 | PMCID: PMC11527383
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, [...] Kumar R
J Natl Compr Canc Netw, 22(5):331-357, 01 Jul 2024
Cited by: 8 articles | PMID: 39019058
Add to export list
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Boscolo Bielo L, Trapani D, Nicolò E, Valenza C, Guidi L, Belli C, Kotteas E, Marra A, Prat A, Fusco N, Criscitiello C, Burstein HJ, Curigliano G
Cancer Treat Rev, 128:102761, 16 May 2024
Cited by: 1 article | PMID: 38772169
Add to export list Review
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
Valenza C, Trapani D, Loibl S, Chia SKL, Burstein HJ, Curigliano G
J Clin Oncol, 42(20):2372-2376, 03 Apr 2024
Cited by: 0 articles | PMID: 38569132
Add to export list
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, [...] Tolaney SM
J Clin Oncol, 42(17):2050-2060, 21 Mar 2024
Cited by: 9 articles | PMID: 38513188
Add to export list
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panel
J Clin Oncol, 42(12):1450-1453, 13 Mar 2024
Cited by: 3 articles | PMID: 38478799
Add to export list
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Higgins T, Kantor O, Harrison B, Giordano J, McGrath M, Burstein HJ, Schnitt SJ, Rahman T, Vora H, Garrido-Castro A, Tolaney SM, Meric-Bernstam F, King TA, Mittendorf EA
Ann Surg Oncol, 31(4):2244-2252, 31 Dec 2023
Cited by: 1 article | PMID: 38161200
Add to export list
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, [...] ESMO Guidelines Committee. Electronic address: [email protected]
Ann Oncol, 35(2):159-182, 13 Dec 2023
Cited by: 61 articles | PMID: 38101773
Add to export list
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Mayer EL, Tayob N, Ren S, Savoie JJ, Spigel DR, Burris HA, Ryan PD, Harris LN, Winer EP, Burstein HJ
Breast Cancer Res Treat, 204(1):123-132, 29 Nov 2023
Cited by: 3 articles | PMID: 38019444
Add to export list
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.
Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thürlimann B, St Gallen Consensus Conference Panelists 2023
Ann Oncol, 34(11):970-986, 06 Sep 2023
Cited by: 43 articles | PMID: 37683978
Add to export list
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, [...] Adalsteinsson VA
Ann Oncol, 34(10):899-906, 18 Aug 2023
Cited by: 10 articles | PMID: 37597579 | PMCID: PMC10898256
Add to export list Free full text in Europe PMC
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
Mayerhofer C, Sedrak MS, Hopkins JO, Li T, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong AR, Tiwari A, McAllister SS, Mittendorf EA, Gibson CJ, [...] Miller PG
J Natl Cancer Inst, 115(8):981-988, 01 Aug 2023
Cited by: 2 articles | PMID: 37042724 | PMCID: PMC10407695
Add to export list Free full text in Europe PMC
Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Burstein HJ, DeMichele A, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels
J Clin Oncol, 41(18):3423-3425, 17 May 2023
Cited by: 25 articles | PMID: 37196213
Add to export list
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, [...] Kumar R
J Natl Compr Canc Netw, 21(6):594-608, 01 Jun 2023
Cited by: 83 articles | PMID: 37308117
Add to export list
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, [...] Curigliano G
Ann Oncol, 34(8):645-659, 01 Jun 2023
Cited by: 52 articles | PMID: 37269905
Add to export list Review
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.
Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJ
JCO Oncol Pract, 19(8):560-570, 16 May 2023
Cited by: 1 article | PMID: 37192427
Add to export list
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, [...] Adalsteinsson VA
medRxiv, 08 Mar 2023
Cited by: 0 articles | PPR: PPR627285
Add to export list Preprint
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, [...] Winer EP
Lancet Oncol, 24(3):273-285, 01 Mar 2023
Cited by: 32 articles | PMID: 36858723
Add to export list
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
Grinshpun A, Tolaney SM, Burstein HJ, Jeselsohn R, Mayer EL
NPJ Breast Cancer, 9(1):15, 22 Mar 2023
Cited by: 9 articles | PMID: 36949066 | PMCID: PMC10033931
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer.
Burstein HJ
Hematol Oncol Clin North Am, 37(1):xiii-xvi, 01 Feb 2023
Cited by: 0 articles | PMID: 36435617
Add to export list
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, [...] SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation)
J Clin Oncol, 41(7):1376-1382, 15 Dec 2022
Cited by: 30 articles | PMID: 36521078 | PMCID: PMC10419413
Add to export list Free full text in Europe PMC
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, [...] SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation)
J Clin Oncol, 41(7):1370-1375, 09 Dec 2022
Cited by: 13 articles | PMID: 36493334 | PMCID: PMC10419521
Add to export list Free full text in Europe PMC

1-25 of 310 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Anthracyclines in Early Breast Cancer: The Long Goodbye.

Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.

Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.

Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.

Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.

Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer.

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.

Partnerships & funding